Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients

Cancer Letters

Volumn 188, Issue 1-2, 2002, Pages 109-114

  An, Qian ^a   Liu, Yong ^b   Gao, Yanning ^a   Huang, Jinfeng ^a   Fong, Xiaoli ^a   Li, Ling ^a   Zhang, Dechao ^a   Cheng, Shujun ^a  

^a CANCER HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hypermethylation; Lung cancer; p16; Plasma

Indexed keywords

BIOLOGICAL MARKER; DNA; PROTEIN P16;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 0037114362     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00496-2     Document Type: Article

References (31)

1. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72:1998;141-196.
2. Gray S.G., Eriksson T., Ekstrom T.J. Methylation, gene expression and the chromatin connection in cancer. Int. J. Mol. Med. 4:1999;333-350.
3. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burge P.C., Baylin S.B., Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
4. Virmani A.K., Rathi A., Sathyanarayana U.G., Padar A., Huang C.X., Cunnigham H.T., Farinas A.J., Milchgrub S., Euhus D.M., Gilcrease M., Herman J.G., Minna J.D., Gazdar A.F. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin. Cancer Res. 7:2001;1998-2004.
5. Brabender J., Usadel H., Danenberg K.D., Metzger R., Schneider P.M., Lord R.V., Wickramasinghe K., Lum C.E., Park J., Salonga D., Singer J., Sidransky D., Holscher A.H., Meltzer S.J., Danenberg P.V. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene. 20:2001;3528-3532.
6. Zochbauer-Muller S., Fong K.M., Maitra A., Lam S., Geradts J., Ashfaq R., Virmani A.K., Milchgrub S., Gazdar A.F., Minna J.D. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 61:2001;3581-3585.
7. Virmani A.K., Rathi A., Zochbauer-Muller S., Sacchi N., Fukuyama Y., Bryant D., Maitra A., Heda S., Fong K.M., Thunnissen F., Minna J.D., Gazdar A.F. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92:2000;1303-1307.
8. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:1999;793-797.
9. Tang X., Khuri F.R., Lee J.J., Kemp B.L., Liu D., Hong W.K., Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 92:2000;1511-1516.
10. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
11. Sato M., Mori Y., Sakurada A., Fujimura S., Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum. Genet. 103:1998;96-101.
12. Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., Randle D., Kondo M., Virmani A., Bader S., Sekido Y., Latif F., Milchgrub S., Toyooka S., Gazdar A.F., Lerman M.I., Zabarovsky E., White M., Minna J.D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 93:2001;691-699.
13. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., Baylin S.B., Graff J.R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59:1999;798-802.
14. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., Baylin S.B., Herman J.G. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA. 95:1998;11891-11896.
15. Stroun M., Anker P., Maurice P., Lyautey J., Lederrey C., Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 46:1989;318-322.
16. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:1977;646-650.
17. Hibi K., Taguchi M., Nakayama H., Takase T., Kasai Y., Ito K., Akiyama S., Nakao A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 7:2001;3135-3138.
18. Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G.H., Koch W.M., Jen J., Herman J.G., Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60:2000;892-895.
19. Wong I.H., Lo Y.M., Zhang J., Liew C.T., Ng M.H., Wong N., Lai P.B., Lau W.Y., Hjelm N.M., Johnson P.J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59:1999;71-73.
20. Shapino B., Chakrabaty M., Cohn E., Leon S.A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 51:1983;2116-2120.
21. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:2000;5954-5958.
22. Whetsell L., Maw G., Nadon N., Ringer D., Schaefer F. Polymerase chain reaction microanalysis of tumors from stained histological slides. Oncogene. 7:1992;2355-2361.
23. Herman J.G., Graff J.T., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93:1996;9821-9826.
24. Jarrard D.F., Bova G.S., Ewing C.M., Pin S.S., Nguyen S.H., Baylin S.B., Cairns P., Sidransky D., Herman J.G., Isaacs W.B. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer. 19:1997;90-96.
25. Chen X.Q., Stroun M., Magnenat J.L., Nicod L.P., Kurt A.M., Lyautey J., Lederrey C., Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 2:1996;1033-1035.
26. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 2:1996;1035-1037.
27. Kopreski M.S., Benko F.A., Kwee C., Leitzel K.E., Lipton A., Gocke C.D. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer. 76:1997;1293-1299.
28. Hibi K., Robinson R., Wu L., Hamilton S.R., Sidransky D., Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 58:1997;1405-1407.
29. Mulcahy H.E., Lyautey J., Lederrey C., Chen X., Anker P., Alstead E.M., Ballinger A., Farthing M.J.G., Stroun M.A. Prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res. 4:1998;271-275.
30. Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M.A. Point mutations of the N-ras in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 86:1994;774-779.
31. Myohanen S.K., Baylin S.B., Herman J.G. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58:1998;591-593.